Inventor · disambiguated record
Vasant Jadhav
Also filed as: JADHAV VASANT · JADHAV VASANT R
50 granted patents·64 pending applications·401 citations·filing 2003–2025
98Inventor score
Files withALNYLAM PHARMACEUTICALS INC68SIRNA THERAPEUTICS INC28JADHAV VASANT8MERCK & CO INC4AARONSON JEFFREY G1
Top patents by PatentIndex Score
114 records- 0198US10612024B2Modified double-stranded RNA agentsALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Apr 7, 2020·15 cites·35 claims
- 0298US10612027B2Modified double-stranded RNA agentsALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Apr 7, 2020·26 cites·25 claims
- 0398US10233448B2Modified double-stranded RNA agentsALNYLAM PHARMACEUTICALS INC·Filed 2015·Granted Mar 19, 2019·37 cites·40 claims
- 0498US7858769B2RNA interference mediated inhibition of gene expression using multifunctional short interfering nucleic acid (multifunctional siNA)SIRNA THERAPEUTICS INC·Filed 2005·Granted Dec 28, 2010·156 cites·16 claims
- 0597US11286486B2Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseasesALNYLAM PHARMACEUTICALS INC·Filed 2020·Granted Mar 29, 2022·8 cites·28 claims
- 0696US11504391B1Modified RNA agents with reduced off-target effectALNYLAM PHARMACEUTICALS INC·Filed 2017·Granted Nov 22, 2022·18 cites·42 claims
- 0796US11401517B2Modified double-stranded RNA agentsALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Aug 2, 2022·6 cites·24 claims
- 0895US10683501B2Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseasesALNYLAM PHARMACEUTICALS INC·Filed 2018·Granted Jun 16, 2020·8 cites·28 claims
- 0995US10208307B2Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseasesALNYLAM PHARMACEUTICALS INC·Filed 2016·Granted Feb 19, 2019·16 cites·75 claims
- 1094US12385044B2Modified double-stranded RNA agentsALNYLAM PHARMACEUTICALS INC·Filed 2024·Granted Aug 12, 2025·0 cites·30 claims
- 1194US10995336B2Serpina1 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted May 4, 2021·8 cites·41 claims
- 1293US12385043B2Modified double-stranded RNA agentsALNYLAM PHARMACEUTICALS INC·Filed 2024·Granted Aug 12, 2025·0 cites·35 claims
- 1392US12049628B2Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseasesALNYLAM PHARMACEUTICALS INC·Filed 2022·Granted Jul 30, 2024·1 cites·44 claims
- 1492US7935812B2RNA interference mediated inhibition of hepatitis C virus (HCV) expression using short interfering nucleic acid (siNA)MERCK SHARP & DOHME·Filed 2009·Granted May 3, 2011·28 cites·13 claims
- 1592US7517864B2RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)SIRNA THERAPEUTICS INC·Filed 2005·Granted Apr 14, 2009·16 cites·16 claims
- 1691US11492623B2Hepatitis B virus (HBV) dsRNA agent compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Nov 8, 2022·4 cites·36 claims
- 1791US10829763B2TMPRSS6 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Nov 10, 2020·4 cites·17 claims
- 1891US10689648B2Short interfering nucleic acid (siNA) compositionsSIRNA THERAPEUTICS INC·Filed 2017·Granted Jun 23, 2020·5 cites·19 claims
- 1990US10513703B2Hepatitis B virus (HBV) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2017·Granted Dec 24, 2019·6 cites·24 claims
- 2089US11060091B2Hepatitis B virus (HBV) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Jul 13, 2021·2 cites·45 claims
- 2188US12168767B2Modified double-stranded RNA agentsALNYLAM PHARMACEUTICALS INC·Filed 2022·Granted Dec 17, 2024·0 cites·25 claims
- 2288US11725207B2Serpina1 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Aug 15, 2023·1 cites·123 claims
- 2388US10246713B2TMPRSS6 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2017·Granted Apr 2, 2019·6 cites·14 claims
- 2488US2025075211A1TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED DISEASESALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 2587US10729787B2Systemic delivery of myostatin short interfering nucleic acids (siNA) conjugated to a lipophilic moietySIRNA THERAPEUTICS INC·Filed 2018·Granted Aug 4, 2020·2 cites·12 claims
- 2686US12378553B2Modified double-stranded RNA agentsALNYLAM PHARMACEUTICALS INC·Filed 2022·Granted Aug 5, 2025·0 cites·43 claims
- 2786US11725209B2TMPRSS6 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2020·Granted Aug 15, 2023·1 cites·20 claims
- 2885US11597932B2Chirally-enriched double-stranded RNA agentsALNYLAM PHARMACEUTICALS INC·Filed 2018·Granted Mar 7, 2023·3 cites·24 claims
- 2985US11549109B2Modified double-stranded RNA agentsALNYLAM PHARMACEUTICALS INC·Filed 2022·Granted Jan 10, 2023·0 cites·30 claims
- 3085US2025236871A1Multi-targeted single entity conjugatesALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 3185US2025207131A1Modified rna agents with reduced off-target effectALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 3283US12005074B2Extrahepatic deliveryALNYLAM PHARMACEUTICALS INC·Filed 2023·Granted Jun 11, 2024·0 cites·28 claims
- 3383US11530407B2Short interfering nucleic acid (siNA) compositionsSIRNA THERAPEUTICS INC·Filed 2020·Granted Dec 20, 2022·1 cites·25 claims
- 3483US2025043279A1SERPINA1 iRNA COMPOSITIONS AND METHODS OF USE THEREOFALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 3583US2024358738A1Extrahepatic deliveryALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 3682US11427822B2Modified double-stranded RNA agentsALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Aug 30, 2022·0 cites·24 claims
- 3782US11034957B2Amyloid precursor protein (APP) RNAi agent compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2020·Granted Jun 15, 2021·1 cites·30 claims
- 3881US2022002727A1Modified double-stranded rna agentsALNYLAM PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 3980US12486503B2Short interfering nucleic acid (siNA) compositionsSIRNA THERAPEUTICS INC·Filed 2022·Granted Dec 2, 2025·0 cites·18 claims
- 4079US12275938B2Modified RNA agents with reduced off-target effectALNYLAM PHARMACEUTICALS INC·Filed 2022·Granted Apr 15, 2025·0 cites·38 claims
- 4179US2023144623A1Systemic delivery of myostatin short interfering nucleic acids (sina) conjugated to a lipophilic moietySIRNA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4277US10933081B2Myostatin iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2017·Granted Mar 2, 2021·1 cites·20 claims
- 4376US12241064B2REVERSIR™ compoundsALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Mar 4, 2025·0 cites·25 claims
- 4476US10004814B2Systemic delivery of myostatin short interfering nucleic acids (siNA) conjugated to a lipophilic moietySIRNA THERAPEUTICS INC·Filed 2014·Granted Jun 26, 2018·2 cites·14 claims
- 4576US2025059536A1Tunable reversir tm compoundsALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 4676US2024200061A1TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED OCULAR DISEASESALNYLAM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 4776US2023256001A1Modified rna agents with reduced off-target effectALNYLAM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 4874US12221607B2Multi-targeted single entity conjugatesALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Feb 11, 2025·0 cites·24 claims
- 4973US12018260B2Tunable Reversir™ compoundsALNYLAM PHARMACEUTICALS INC·Filed 2022·Granted Jun 25, 2024·0 cites·19 claims
- 5072US12247203B2Modified RNA agents with reduced off-target effectALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Mar 11, 2025·0 cites·20 claims
Showing the top 50 of 114 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Vasant Jadhav files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →